focus -WSS

focus

author：focus 2025-09-27 22:06:16 - browse：45326

U.S. Sen. Bernie Sanders sets his hands on two chairs as two people set up a board displaying a "price of drugs" chart behind him — politics coverage from STAT — Sen. Bernie Sanders has used his leadership of a Senate committee to pressure drugmakers to lower their prices. Kevin Dietsch/Getty Images

WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him.

For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. After a few victories he’s claimed — experts say some credit is deserved, but the full story is a bit more complicated — he’s now progressed to demanding that Novo Nordisk cut its price for its novel, wildly popular diabetes and weight-loss drugs.

Sanders (I-Vt.) is testing the limits of the powers of a Senate chairman with little hope of advancing his policy agenda legislatively. He’s threatened subpoenas, held a prominent nominee hostage, and initiated investigations to get his way. It’s a sharp departure from the modest, bipartisan ambitions that more disciplined, discreet leaders of the committee have taken in years past, and sets the bar for how much can be accomplished using the full extent of the bully pulpit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： In search for therapies for solid tumors, companies turn to claudin

leisure time

WSS

First transplant of an entire human eye performed

ALS groups 'won't be played again' by the FDA, drug sponsors

A Q&A with Aletha Maybank, AMA’s chief health equity officer

NIH chief: government has fallen behind pharma on clinical trials

What health policies could hitch a ride on a spending bill?

RSV vaccines may be linked to small increased risk of developing GBS

Wikipedia

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

focus

The cancer drug shortage isn’t new — and neither are the solutions

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Hollywood unions extend contract negotiations for actors

Why getting cancer drugs just got harder for rural patients

The cancer drug shortage isn’t new — and neither are the solutions

AstraZeneca loses challenge to Medicare drug price negotiation

Medical records are filled with copy

FDA reorg will put new emphasis on investigations, sources say

Walensky prepares to leave CDC — and Congress — behind

Ohio still needs to do more to protect the right to abortion

leisure time

After decades in use, heart stents finally beat placebo

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Kenai launches with $82 million for Parkinson’s stem cell therapy

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

RSV vaccines may be linked to small increased risk of developing GBS

A letter from the executive editor: STAT UnitedHealth investigation

leisure time

knowledge

entertainment

hotspot